YeastSaccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin Mary-Ann BjornstiAnne M. KnabPiero Benedetti Session 1: Topoisomerase Basic Science Pages: S1 - S5
Using yeast to study resistance to topoisomerase II-targeting drugs John L. Nitiss Session 1: Topoisomerase Basic Science Pages: S6 - S13
Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells William T. BeckRyungsa KimMei Chen Session 1: Topoisomerase Basic Science Pages: S14 - S18
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes Neil OsheroffAnita H. CorbettMajken Westergaard Session 1: Topoisomerase Basic Science Pages: S19 - S25
Structure-activity relationships of VP-16 analogues Byron H. LongAnna-Maria Casazza Session 1: Topoisomerase Basic Science Pages: S26 - S31
Topoisomerase expression in cancer cell lines and clinical samples L. Austin Doyle Session 1: Topoisomerase Basic Science Pages: S32 - S40
Preclinical and phase I trials of topoisomerase I inhibitors Daniel D. Von HoffHoward A. Burris IIIJohn G. Kuhn Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S41 - S45
Clinical, pharmacokinetic and biological studies of topotecan Peter J. O'DwyerFrank P. LaCretaKang-Shen Yao Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S46 - S52
Camptothecin analogues: studies from The Johns Hopkins Oncology Center William J. SlichenmyerEric K. RowinskyRoss C. Donehower Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S53 - S57
Clinical and pharmacokinetic overview of parenteral etoposide phosphate Lee P. SchacterLinus N. IgwemeziePedro Santabárbara Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S58 - S63
Pharmacodynamics and long-term toxicity of etoposide Ken KobayashiMark J. Ratain Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S64 - S68
Etoposide dosage and pharmacodynamics Simon P. JoelRita ShahMaurice L. Slevin Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S69 - S75
Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations Clinton F. Stewart Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S76 - S83
Schedule-dependent topoisomerase II-inhibiting drugs Simon P. JoelMaurice L. Slevin Session 2: Pharmacology: Preclinical and Phase I Studies of Topoisomerase Dosing Concepts Pages: S84 - S88
Epipodophyllotoxins in the treatment of childhood cancer Gaston K. RiveraChing-Hon PuiWilliam M. Crist Session 3: Clinical Trials and Applications Pages: S89 - S95
Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer Desmond N. CarneyAnthony Byrne Session 3: Clinical Trials and Applications Pages: S96 - S100
Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? F. Anthony GrecoJohn D. Hainsworth Session 3: Clinical Trials and Applications Pages: S101 - S104
Clinical studies of irinotecan alone and in combination with cisplatin Masahiro FukuokaNoriyuki Masuda Session 3: Clinical Trials and Applications Pages: S105 - S111
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials Nagahiro SaijoKazuto NishioMakoto Nishio Session 3: Clinical Trials and Applications Pages: S112 - S117
Etoposide: current status and future perspectives in the management of malignant neoplasms Chandra P. BelaniL. Austin DoyleJoseph Aisner Session 3: Clinical Trials and Applications Pages: S118 - S126
Teniposide: overview of its therapeutic potential in adult cancers Franco M. Muggia Session 3: Clinical Trials and Applications Pages: S127 - S133